Full text is available at the source.
Low incidence of anti‐drug antibodies in patients with type 2 diabetes treated with once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide
Rare immune reactions in type 2 diabetes patients treated weekly with dulaglutide
AI simplified
Abstract
In a study involving 4006 patients, 1.6% developed anti-drug antibodies (ADAs) after treatment with the glucagon-like peptide-1 receptor agonist dulaglutide.
- Dulaglutide ADAs were present in 64 patients, compared to 0.7% in the non-GLP-1 comparator group.
- Among the ADA-positive patients, 34 had neutralizing ADAs, indicating potential reduced efficacy.
- The incidence of hypersensitivity adverse events and injection site reactions was similar between dulaglutide and placebo groups.
- No patients with dulaglutide ADAs reported hypersensitivity adverse events.
- Due to the low incidence of ADAs, their impact on glycaemic control could not be determined.
AI simplified